Hess and colleagues assert that hemorrhagic risk from reduced blood product potency of pathogen-reduced (PR) platelets and PR plasma for patients with trauma and other indications for massive transfusion is an important consideration in risk-based decision making for implementing PR.
The Company's first product is the Platelet PGD Test – a rapid test for the detection of bacterial contamination in platelets.